# Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer

> **NCT03723915** · PHASE2 · TERMINATED · sponsor: **Northwestern University** · enrollment: 17 (actual)

## Conditions studied

- Pancreatic Adenocarcinoma
- Stage III Pancreatic Cancer AJCC v8
- Stage IV Pancreatic Cancer AJCC v8

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **BIOLOGICAL:** Wild-type Reovirus

## Key facts

- **NCT ID:** NCT03723915
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-11-14
- **Primary completion:** 2019-12-19
- **Final completion:** 2021-04-24
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** The total accrual goal of 34 patients was not met. Stage 1 of the study did not meet the interim analysis criteria to move onto Stage 2 of the Simon 2 stage design.
- **Last updated:** 2022-10-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03723915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03723915, "Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03723915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*